Drug Trial Radar · NCT02172872
"InDACtion" vs "3+7" Induction in AML
Last checked: Nov 20, 2026Latest source record: Feb 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
606
Actual
Start
Nov 28, 2014
Primary completion
Mar 7, 2022
Study completion Dec 2023
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- Collaborators
- Janssen Pharmaceuticals; Gruppo Italiano Malattie EMatologiche dell'Adulto
- First posted
- Jun 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the treatment of elderly AML patients with intensive chemotherapy, the survival has not been improved during the last decades. The purpose of this study is to determine whether frontline therapy with a 10-day decitabine schedule provides a better survival than standard intensive combination chemotherapy in elderly AML patients (\>= 60 years).
Conditions
- Acute Myeloid Leukemia (AML)
Interventions
standard combination chemotherapyDrug
1. Cycle 1 1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days 2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days. 2. Cycle 2 1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days 2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days. 3. Cycle 3 (mini-ICE) 1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days 2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days 3. etoposide (100 mg/m²) infusion (1 hr) for 3 days 4. Cycle 4 (mini-ICE) (optional) 1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days 2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days 3. etoposide (100 mg/m²) infusion (1 hr) for 3 days
decitabineDrug
1. Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days 2. Cycle 2 1. if bone marrow (BM) blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days 2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days 3. Cycle 3 1. if BM blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days 2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days 4. Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days 5. Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: 4.9 years from first patient in
Locations
53 sites in 9 countries. Site status is shown where the registry gives one.
Institut Jules Bordet
Brussels, Belgium
C.H.U. Sart-Tilman
Liège, Belgium
CHR De La Citadelle
Liège, Belgium
UZ Antwerpen
Edegem, Antwerpen, Belgium
UZ Brussel
Jette, Brussels Capital, Belgium
CHR Verviers
Verviers, Liège, Belgium
A.Z. St. Jan
Bruges, West-Vlaanderen, Belgium
National Specialized Hospital for Active Treatment of Haematological Diseases
Sofia, Bulgaria
Clinical Hospital Merkur
Zagreb, Croatia
University Hospital Rebro
Zagreb, Croatia
CHU de Caen - Hôpital Côte de Nacre
Caen, France
CHU de Nantes - Hôtel Dieu
Nantes, France
Assistance Publique - Hôpitaux de Paris - Hôpital Saint Antoine
Paris, France
Universitätsklinikum Aachen AÖR - Medizinische Fakultät der RWTH
Aachen, Germany
Klinikum Augsburg
Augsburg, Germany
Helios Kliniken - Helios Klinikum Berlin-Buch
Berlin, Germany
Universitätsklinikum Essen
Essen, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitaetklinikum Halle - Martin Luther Universitaet - Universitaetsklinikum Halle (Saale)
Halle, Germany
Klinikum Der Phillips - Universität Marburg
Marburg, Germany
Universitaet Rostock - Medizinische Fakultaet
Rostock, Germany
Universitaetsklinikum Tuebingen-Uni Kliniken Berg
Tübingen, Germany
Azienda Ospedaliero Universitaria - Ospedali Riuniti
Ancona, Italy
Universita Degli Studi Di Bari - Policlinico
Bari, Italy
Universita di Bologna
Bologna, Italy
Ospedale Regionale A. Pugliese
Catanzaro, Italy
Ospedali Riuniti Foggia
Foggia, Italy
Azienda Ospedaliero - Universitaria Policlinico di Modena
Modena, Italy
Amedeo Avogadro University of Eastern Piedmont-Ospedale Maggiore della Carita
Novara, Italy
La Maddalena S.P.A.
Palermo, Italy
Ospedale San Salvatore
Pesaro, Italy
AUSL Romagna - Ospedale Santa Maria dell Croci
Ravenna, Italy
Arcispedale Di S. Maria Nuova
Reggio Emilia, Italy
AUSL Romagna - Ospedale Infermi di Rimini
Rimini, Italy
H. San Giovanni - Addolorata
Roma, Italy
Universita Degli Studi Di Roma La Sapienza - Ospedale Sant'Andrea
Roma, Italy
Azienda Ospedallera Universitaria - Policlinico Tor Vergata
Rome, Italy
Instituto Regina Elena / Instituti Fisioterapici Ospitalieri
Rome, Italy
Ospedale San Eugenio
Rome, Italy
Clinica Ematologica dell'Universita di Roma La Sapienza
Rome, Italy
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.